Pfizer lung cancer drug misses survival goal in Phase 3 trial
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced topline results from its Phase 3 SigVie-002 study evaluating sigvotatug vedotin, an investigational integrin beta-6 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
